Stocks Health care BDTX
NASDAQ · Health careBlack Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $42.6M. At June 30, 2026 it held $19.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Black Diamond Therapeutics, Inc.
- Net worth
- Black Diamond Therapeutics, Inc. has a market value (market cap) of $106.9M at the latest share price, and shareholders' equity of $96.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $70M, with net income of $22.4M. Over the 12 months to June 30, 2026: revenue $0, net loss $42.6M.
- Cash flow
- In fiscal 2025 operations brought in $29.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Black Diamond Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Black Diamond Therapeutics, Inc. does
Black Diamond Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BDTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $70M | $22.4M | $0.39 | n/a |
| 2024 | $0 | -$69.7M | -$1.27 | -$62.3M |
| 2023 | n/a | -$82.4M | -$1.88 | -$66.8M |
| 2022 | n/a | -$91.2M | -$2.52 | -$85.3M |
| 2021 | n/a | -$125.6M | -$3.47 | -$102.9M |
| 2020 | $0 | -$67.3M | -$2.05 | -$52.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BDTX ranks in Health care
Latest SEC filings
What Black Diamond Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026
- August 5, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 29, 2026
- May 21, 2026
- May 7, 2026
- May 7, 2026
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
Insider trades
What the people running Black Diamond Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Behbahani AliDirector | Received as pay | 7,707 | $14.9K |
| September 18, 2026 | Raman PrakashDirector | Received as pay | 6,801 | $13.1K |
| June 19, 2026 | Behbahani AliDirector | Received as pay | 8,961 | $14.9K |
| June 19, 2026 | Raman PrakashDirector | Received as pay | 7,907 | $13.1K |
| March 20, 2026 | Behbahani AliDirector | Received as pay | 6,919 | $14.9K |
| March 20, 2026 | Raman PrakashDirector | Received as pay | 6,105 | $13.1K |
| December 12, 2025 | Behbahani AliDirector | Received as pay | 5,208 | $14.4K |
| December 12, 2025 | Raman PrakashDirector | Received as pay | 4,665 | $12.9K |
Who owns BDTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ali Behbahani13D, may seek influence with 9 related filers | 8.1% | May 13, 2024 |
| Versant Ventures VI GP, L.P.13D, may seek influence with 9 related filers | 7.7% | August 8, 2024 |
| T. Rowe Price Investment Management, Inc.13G, passive | 7% | July 8, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 162,076 shares in total, about $301.5K at the last price.
| Holder | Shares |
|---|---|
| Behbahani AliDirector | 110,236 |
| Raman PrakashDirector | 51,840 |
Questions about BDTX
What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as BDTX. Its shares trade on NASDAQ under the ticker BDTX.
What is Black Diamond Therapeutics, Inc.'s net worth?
Black Diamond Therapeutics, Inc. has a market value (market cap) of $106.9M at the latest share price, and shareholders' equity of $96.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Black Diamond Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $42.6M.
How much revenue does Black Diamond Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Black Diamond Therapeutics, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Black Diamond Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 21, 2026.
When is Black Diamond Therapeutics, Inc.'s next earnings report?
Black Diamond Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare BDTX with
Follow BDTX
Get an email when Black Diamond Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Black Diamond Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.